secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intra-Cellular Therapies, Inc. (—)
CIK:        0001567514
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-070838
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intra-Cellular Therapies promotes Michael Halstead to President; CFO Hineline to retire
--------------------------------------------------------------------------------

- Michael Halstead, former EVP & General Counsel, promoted to President effective March 19, 2024.
- Halstead's base salary increased to $636,540; receives 36,717 time-based RSUs and 12,240 performance-based RSUs.
- CFO Lawrence Hineline intends to retire after 20+ years; company has initiated external search for successor.
- Hineline will remain through transition; departure not due to any disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/d800974d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer